Exclusion of HIV-Positive Individuals in US Psychedelic Trials

HIV-Positive Individuals Excluded from Pivotal Psychedelic Trials

Most pivotal clinical trials of psychedelic therapies in the United States, including those for MDMA-assisted therapy and psilocybin, have systematically excluded people living with HIV. This exclusion is documented in trial protocols and eligibility criteria for major studies registered on ClinicalTrials.gov and is highlighted in recent commentary as the US Food and Drug Administration (FDA) approaches key decisions on these substances. The absence of HIV-positive participants raises immediate concerns about the generalizability of safety and efficacy data for a population with unique medical needs and comorbidities.

Mechanisms Behind Exclusion and Clinical Context

Exclusion of HIV-positive individuals from psychedelic trials is typically justified by concerns about drug-drug interactions, immune status, and potential for atypical adverse events. For example, many protocols for MDMA (3,4-methylenedioxymethamphetamine) and psilocybin trials list "active infectious disease" or "immunocompromised state" as exclusion criteria, often without detailed risk stratification. This blanket approach may stem from a lack of pharmacokinetic data on psychedelic-antiretroviral interactions and limited precedent for including immunocompromised populations in psychiatric trials.

However, modern antiretroviral therapy (ART) has transformed HIV into a chronic, manageable condition for most patients in the US. Many people with HIV have stable immune function and are at no greater risk of acute infection than the general population. The continued exclusion of this group, despite advances in HIV care, reflects a conservative risk management strategy rather than evidence-based assessment. Notably, such exclusions can mask potential safety signals or efficacy differences relevant to real-world clinical practice.

Policy, Research, and Access Implications

The exclusion of people with HIV from psychedelic trials has direct implications for regulatory approval, insurance coverage, and clinical practice guidelines. The FDA, in its review process, relies on trial data to determine both the generalizability of findings and the scope of approved indications. If HIV-positive individuals are not represented, labeling may include restrictive language or require post-marketing studies to address safety in this population. This could delay or limit access for a group that already faces barriers to mental health care.

For researchers and sponsors, there is increasing pressure to broaden eligibility criteria in ongoing and future studies. The National Institutes of Health (NIH) and advocacy groups have called for more inclusive trial designs, especially as evidence mounts that people living with HIV experience higher rates of depression, trauma, and substance use disorders—conditions under investigation for psychedelic-assisted therapy. A non-obvious consequence is that exclusion may also limit the ability to detect rare but serious adverse events, such as serotonin syndrome or immunological reactions, that could be more prevalent or present differently in immunocompromised populations.

Risks, Unknowns, and Gaps in Evidence

The primary risk of including HIV-positive individuals in psychedelic trials is the potential for unanticipated drug-drug interactions, particularly with ritonavir-boosted regimens that affect cytochrome P450 enzymes involved in psychedelic metabolism. However, the lack of systematic pharmacokinetic studies means these risks are largely theoretical. Another unknown is whether chronic inflammation or immune activation in HIV alters the neurobiological response to psychedelics, potentially affecting both efficacy and side effect profiles.

Conversely, the risk of exclusion is that clinicians will lack data to inform safe prescribing, leading to off-label use without evidence-based guidance. This is especially salient given the high prevalence of mental health comorbidities among people with HIV. A concrete failure mode, rarely discussed in competitor coverage, is that future real-world use may reveal safety signals missed in trials, prompting regulatory action or black box warnings that could have been preempted by more inclusive research.

Looking Ahead: Toward More Inclusive Psychedelic Research

As the FDA prepares to issue decisions on MDMA-assisted therapy (expected in early 2027, see FDA psychedelics page) and psilocybin (Phase 3 trials ongoing, NCT05660642), sponsors and investigators face mounting ethical and scientific pressure to address the exclusion of HIV-positive individuals. Some trialists are now piloting sub-studies or expanded access protocols specifically for this population, though these efforts remain preliminary.

For the field to advance equitably and safely, future trials must include robust pharmacokinetic assessments, stratified safety monitoring, and explicit plans for post-marketing surveillance in populations with HIV and other chronic conditions. Only through such measures can psychedelic medicine fulfill its promise without perpetuating historical inequities in research and care.

By Dr. Alex R. Kim, MD, MPH. Reviewed by Dr. Jamie L. Harris, PharmD, on 2026-11-12. Research based on FDA, ClinicalTrials.gov, and sponsor protocols as of November 2026.